talimogene laherparepvec
talimogene laherparepvec is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including Imlygic. Available dosage form: injection, suspension.
Drug Details
- Generic Name
- talimogene laherparepvec
- Brand Names
- Imlygic
- Application Number
- BLA125518
- Sponsor
- Amgen Inc
- NDC Codes
- 4
- Dosage Forms
- INJECTION, SUSPENSION
- Routes
- INTRALESIONAL
- Active Ingredients
- TALIMOGENE LAHERPAREPVEC
Indications and Usage
1 INDICATIONS AND USAGE IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases. IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases. ( 1 )